TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05682911
Drug: Zingiber officinale L. tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zingiber officinale L. tablets 500mg twice daily
Study: NCT05682911
Drug: Simvastatin 20mg
Normalized name: SIMVASTATIN 20MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin 20mg once a day for 2 months
Study: NCT02096328
Drug: POL7080
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion
Study: NCT00892112
Drug: Intravenous Immunoglobulins
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 gr/kg body weight of intravenous immunoglobulin product Nanogam® administered as 0.5 gr/kg IV over a period of 6 hours on each of 4 consecutive days
Study: NCT00892112
Drug: plasma volume expander
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml/kg BW will be administrated on four consecutive days.
Study: NCT01487317
Drug: placebo patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: One transdermal patch of placebo per day from randomization to day 14 Before day 14: end of treatment if DRS R-98 severity \< 10 during 2 consecutive days, At day 14 if DRS R-98 severity ≥ 10: One transdermal patch of placebo per day from day 14 to day 30 if DRS R-98 severity \< 10, the placebo treatment will be stopped
Study: NCT01030861
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for Teplizumab
Study: NCT01686555
Drug: ABT-199
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT04402866
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to be administered by inhalation
Study: NCT02362529
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg and 100 mg capsule, oral administration
Study: NCT02362529
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg and 200 mg capsules, oral administration.
Study: NCT03351972
Drug: Klean Prep
Normalized name: Noxzema Clean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants randomised to use polyethylene glycol will follow either routine guidance of taking the bowel prep the night before their capsule endoscopy or receive guidance that they should split their dose between the night before and the morning of the procedure
Study: NCT02660710
Drug: R-CHOP
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: maximum of 6-8 cycles of R-CHOP over 18-24 weeks
Study: NCT02816151
Drug: full dose at 16 UI/kg for Dysport or 6,5 UA/kg for Botox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
Study: NCT02816151
Drug: half dose at 8 UI/kg for Dysport or 3,25 UA/kg for Botox
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
Study: NCT00754338
Drug: Alcon Opti-Free® RepleniSH® with Supraclens®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed Multipurpose Disinfecting Care System + Marketed contact lens protein remover
Study: NCT00754338
Drug: Alcon Opti-Free® RepleniSH®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed Multipurpose Disinfecting Care System
Study: NCT00754338
Drug: B&L ReNu MultiPlus™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marketed Multipurpose Disinfecting Care Systems
Study: NCT02351219
Drug: FOLFOXIRI
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04358081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03103087
Drug: Estradiol/norethindrone acetate
Normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily.
Study: NCT01256411
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received LCZ696 200 mg as the starting dose with optional down titration to 100 mg for tolerance and optional up titration to 400 mg for adequate blood pressure control.
Study: NCT03128996
Drug: RIC regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days -60 to -21: hydroxyurea (30mg/kg/day po) \>6hrs prior to 1st dose: alemtuzumab (3mg IV) Day -21: alemtuzumab (10mg IV or S/C) Day -20: alemtuzumab (15mg IV or S/C) (10mg if \< 10kg) Day -19: alemtuzumab (20mg IV or S/C) (10mg if \< 10kg) Days -8 to -4: fludarabine (30mg/m2/day IV) Day -4: thiotepa (8mg/kg IV) Day -3: melphalan (140mg/m2) Days -2 to -1: rest days/no therapy Day 0: bone marrow transplant
Study: NCT03128996
Drug: GVHD prophylaxis regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day +3 to +4: cyclophosphamide (50mg/kg/day IV) Day +5: Start of tacrolimus \& Start of mycophenolate mofetil (MMF) Days +5, +14, +30, +60, +90: abatacept (IND) (10mg/kg/day IV) Days +120 to +390: abatacept (IND) monthly (5mg/kg/day IV)
Study: NCT03103087
Drug: Estradiol/norethindrone acetate placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily and designed to match the capsule containing E2/NETA in size, shape, color, and odor.
Study: NCT01279499
Drug: Propofol- Remifentanyl
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (doses based on ideal body weight).~Every rise of BP or HR \> 15% of baseline will be followed by a Remifentanyl bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remifentanyl from 0.1 to 1.0 μg/kg/min
Study: NCT01279499
Drug: Propofol, Remifentanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW). General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (ideal body weight).~The depth of anesthesia will be adjusted so as to accomplish a BIS score between 40 and 50 Every rise of BP or HR \> 15% of baseline will be followed by a Remi bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remi from 0.1 to 1.0 μg/kg/min
Study: NCT00232492
Drug: Placebo males
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline bolus (Placebo-control) males
Study: NCT00232492
Drug: Placebo females
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline bolus (Placebo-control) females
Study: NCT01292239
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule taken by mouth once daily for 12 weeks
Study: NCT01292239
Drug: TMC435
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100-mg capsule taken by mouth once daily for 12 weeks
Study: NCT00908570
Drug: estriol
Normalized name: Estriol
DrugBank: Estriol (DB04573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml vaginal cream (1.0 mg estriol/1 ml cream), 3 days/week for approximately 2 months.
Study: NCT00908570
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream
Study: NCT00459563
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once a week for 3 weeks
Study: NCT00404287
Drug: Fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04491240
Drug: Placebo inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day during 10 days inhalation of 3 ml special solution free of nanoparticles (exosomes).
Study: NCT00729404
Drug: Ethinylestradiol/Gestodene (BAY86-5016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal patch: 0.55mg EE+2.1mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles)
Study: NCT04086602
Drug: IZD334
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Drug
Study: NCT04086602
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Match
Study: NCT00729404
Drug: Ethinylestradiol/Gestodene (BAY86-5016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: transdermal patch: 0.55mg EE+1.05 mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles
Study: NCT00427440
Drug: AMG 102 at 20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
Study: NCT01846182
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT02181985
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03923933
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone
Study: NCT03923933
Drug: Bumetanide
Normalized name: Bumetanide
DrugBank: Bumetanide (DB00887)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bumetanide
Study: NCT00460837
Drug: bowel preparation: senna & gastrofin versus picolax (standard)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The intervention is a bowel cleansing procedure
Study: NCT04160325
Drug: azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azathioprine
Study: NCT02275065
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match bictegravir administered orally once daily
Study: NCT00377403
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment:~Dose: 500mg every 4 to 6 hours for pain or fever
Study: NCT03451734
Drug: antipsychotic medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: olanzapine, risperidone, aripiprazole, amisulpride, ziprasidone, and haloperidol groups
Study: NCT03451734
Drug: adjunctive group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: antipsychotic plus placebo, antipsychotic plus sulforaphane(3 tables per day, consisting of 30 mg of SFN-glucosinolate per day), and antipsychotic plus minocycline(200mg per day) groups.
Study: NCT01538732
Drug: alitretinoin
Normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mg capsules (Alitretinoin)will be taken peroral once daily with a meal. Study treatment will be given for a total duration of up to 24 weeks
Study: NCT01278134
Drug: Copegus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
Study: NCT01278134
Drug: RO5024048
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg bid orally, up to 24 weeks
Study: NCT00719862
Drug: Placebo nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00003038
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02982005
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered placebo by subcutaneous (SC) injection until week 12. Administered KHK4827 by SC injection from week 13 until week 62.
Study: NCT02657031
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal Saline 500 cc IV Bolus
Study: NCT01652144
Drug: AT7519M
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00427440
Drug: AMG 102 at 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
Study: NCT01511510
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution Q24 hours for 14 days
Study: NCT01938612
Drug: MEDI4736
Approvals — FDA: no, EMA: no, PMDA: no
Description: MEDI4736 will be administered by IV infusion every 14, 21 or 28 days.
Study: NCT01750073
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01750073
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00115115
Drug: Dopamine infusion to brain dead organ donors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine infusion administered at a dosage of 4µg/kg/min starting after brain death has been proven until to surgical procurement of the kidneys
Study: NCT01563536
Drug: ABT-267
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01563536
Drug: ABT-450
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01563536
Drug: ABT-333
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet
Study: NCT01844752
Drug: NVN1000 1% Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily NVN1000 1% Gel for 12 weeks
Study: NCT01844752
Drug: NVN1000 4% Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily NVN1000 4% Gel for 12 weeks
Study: NCT01844752
Drug: Vehicle Gel
Normalized name: vehicle gel base no.61
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily Vehicle Gel for 12 weeks
Study: NCT00567190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching pertuzumab) was administered intravenously.
Study: NCT02226913
Drug: 2% lidocaine with 1:80,000 epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lidocaine with 1:80,000 epinephrine
Study: NCT02226913
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sterile distilled water (Samen Pharmaceutical Co, Iran)
Study: NCT02332590
Drug: Placebo (for sarilumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
Study: NCT02332590
Drug: Placebo (for adalimumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
Study: NCT00826826
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: From the day of the catheter ablation procedure and 8 weeks forward.
Study: NCT00211705
Drug: Diet+pravastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04598867
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules
Study: NCT04598867
Drug: Afobazol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afobazol 10 mg tabletes
Study: NCT02669784
Drug: Low Dose Contrast (Omnipaque) 40mL
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will be administered a low dose, 40mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
Study: NCT02669784
Drug: Low Dose Contrast (Omnipaque) 50 mL
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will be administered a low dose, 50mL of intravenous contrast (Omnipaque) at a rate of 5mL/sec based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100mL of intravenous contrast at a rate of 4mL/sec.
Study: NCT02571517
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients assigned to experimental group (group 1) will receive iv methylprednisolone 2 mg/kg/day (divided in two doses) doses and/or oral prednisolone 2,5 mg/kg/day (divided in two doses) during 7 days.
Study: NCT01489943
Drug: Rosuvastatin 10 mg
Normalized name: rosuvastatin 10 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects will receive 10 mg tablet of Rosuvastatin orally once daily on Days 4 and 14. Rosuvastatin will be administered with 240 mL of water.
Study: NCT02953301
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02136940
Drug: AMA0076
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02136940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01024608
Drug: Placebo Nasal Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nasal aerosol administered each morning for two weeks.
Study: NCT03253224
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline group receives the same volume of normal saline, administered according to the same method as in the magnesium group.
Study: NCT03846648
Drug: Cypep-1
Normalized name: Cypex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible subjects will be randomized to one of the two treatment groups in a ratio of 1:1 (active:placebo).~The treatment groups are:~* CyPep-1 topical formulation 1% (w/w)~* Vehicle topical formulation (placebo) The minimum set of studied warts is 1 treated common wart per subject. The subjects will be randomly assigned to treatment. During the treatment period topical formulation will be applied daily on to a maximum of 3 warts. One selected wart will serve as target wart, i.e. the primary wart, for detailed analysis. Selection of warts will be based on the feasibility to conduct treatment application and pharmacodynamics (including biopsy sampling) on the region of interest.
Study: NCT03538951
Drug: 20% VDA-1102
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg once-daily for 12 weeks
Study: NCT03174613
Drug: LC51-0255
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
Study: NCT02697851
Drug: Microgynon 30®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02697851
Drug: Evotaz®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00254202
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03174613
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
Study: NCT01091051
Drug: Placebo (Soduim Chloride)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to placebo (10 with PPPP and 10 with PPP) will receive placebo at Weeks 0 and 4 and ustekinumab at Weeks 16 and 20
Study: NCT03920228
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo topical
Study: NCT00005092
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV over 2 hours on days 2 and 3
Study: NCT00206401
Drug: Lantus and short acting analogs Vs NPH and short acting analogs
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02233907
Drug: Ventilat® - metered dose inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02894528
Drug: BioMend without ReproBone
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Post-extraction the socket was filled only by clot and covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
Study: NCT01990846
Drug: Flufirvitide 3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01990846
Drug: Placebo for Flufirvitide-3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03625401
Drug: AD-35 60mg group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: AD-35 60mg QD
Study: NCT03625401
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo: 3 placebo of AD-35 30mg tablets
Study: NCT02119260
Drug: Placebo solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear, colourless solution of aqueous citrate buffer with 4% captisol
Study: NCT02119260
Drug: Placebo suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Visually matching aqueous suspension of hypromellose acetate succinate powder
Study: NCT02119260
Drug: Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching white opaque placebo blend filled capsule
Study: NCT00800839
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.
Study: NCT00265980
Drug: Subcutaneous Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily injections of saline in the same volume as will be used for leptin injections.
Study: NCT01452633
Drug: 0.25% bupivicaine will be injected at the study port site prior to incision
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection will precede the incision
Study: NCT01452633
Drug: Saline will be in injected into the port site prior to closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline will be injected into the port site prior to the closure without any preincisional intervention
Study: NCT01452633
Drug: 0.25% bupivicaine will be injected into the port site prior to closure
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% bupivicaine will be injected into the port site at closure without any preincisional intervention
Study: NCT00967226
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.0 mg/kg orally, 2 per day 4-6 months
Study: NCT02586025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo by IV infusion in 3-week cycles as neoadjuvant treatment (Cycles 1-4)and as adjuvant treatment (Cycles 8-20)
Study: NCT02562872
Drug: DSM265
Approvals — FDA: no, EMA: no, PMDA: no
Description: DSM265 400 mg single oral dose
Study: NCT00155389
Drug: Helicobacter pylori eradication
Normalized name: Helicobacter pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: For subjects who received the first-line treatment, the costs included the initial 13C-UBT, one-week triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and clarithromycin 500mg twice daily), and the confirmatory 13C-UBT. For subjects in whom the initial treatment failed, the costs further included the re-treatment consisting of ten-day triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and levofloxacin 500mg once daily), and the confirmatory 13C-UBT.~The first round of study was between 2004 and 2005, the second round was between 2008 and 2009, and the third round was between 2012 and 2013.
Study: NCT02562872
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match DSM265, single oral dose
Study: NCT01183663
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 by vein on day 1 of a 21 day cycle.
Study: NCT00003617
Drug: clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no